With $9.7b buy, Novartis bets that heart drugs are coming back - STAT

With $9.7b buy, Novartis bets that heart drugs are coming back - STAT

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By MATTHEW HERPER

Novartis' deal for The Medicines Company represents a new chance for a type of cholesterol-lowering drug — and for its CEO.

READ MORE